Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1

-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a...

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , Philadelphia , Pennsylvania , Tim Clackson , Josh Rappaport , Drug Administration , Prnewswire Theseus Pharmaceuticals Inc , Theseus Pharmaceuticals Inc , Exchange Commission , Theseus Pharmaceuticals , Nasdaq , Chief Executive Officer , Investigational New Drug Application , Theseu Form , Quarterly Reports ,